» Articles » PMID: 38106570

Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy

Abstract

Introduction: Complement 3 glomerulopathy (C3G) is a rare inflammatory kidney disease mediated by dysregulation of the alternative complement pathway. No targeted therapy exists for this aggressive glomerulonephritis. Efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) (measured by complement biomarkers) of iptacopan were assessed in patients with C3G.

Methods: In this phase 2, multicenter, open-label, single-arm, nonrandomized study, adults with biopsy-proven, native kidney C3G (native cohort) and kidney transplant recipients with C3G recurrence (recurrent kidney transplant [KT] cohort) received iptacopan twice daily (bid) for 84 days (days 1-21: 10-100 mg; days 22-84: 200 mg). The primary end point was the urine protein-to-creatinine ratio (UPCR; native cohort) and the change in the C3 deposit score of kidney biopsy (recurrent KT cohort). The complement pathway measures included Wieslab assay, soluble C5b9, and serum C3 levels.

Results: A total of 27 patients (16 native cohort and 11 recurrent KT cohort) were enrolled and all completed the study. In the native cohort, UPCR levels decreased by 45% from baseline to week 12 ( = 0.0003). In the recurrent KT cohort, the median C3 deposit score decreased by 2.50 (scale: 0-12) on day 84 versus baseline ( = 0.03). Serum C3 levels were normalized in most patients; complement hyperactivity observed pretreatment was reduced. Severe adverse events (AEs) included post-biopsy hematuria and hyperkalemia. No deaths occurred during the study.

Conclusion: Iptacopan resulted in statistically significant and clinically important reductions in UPCR and normalization of serum C3 levels in the native cohort and reduced C3 deposit scores in the recurrent KT cohort with favorable safety and tolerability. (ClinicalTrials.gov identifier: NCT03832114).

Citing Articles

Assessing C3 glomerulopathy outcomes in children: how concerned should we be?.

Whelan R, Dixon B Pediatr Nephrol. 2025; .

PMID: 40038132 DOI: 10.1007/s00467-025-06734-0.


Factor B as a therapeutic target for the treatment of complement-mediated diseases.

Kavanagh D, Barratt J, Schubart A, Webb N, Meier M, Fakhouri F Front Immunol. 2025; 16:1537974.

PMID: 40028332 PMC: 11868072. DOI: 10.3389/fimmu.2025.1537974.


Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy.

Nester C, Eisenberger U, Karras A, le Quintrec M, Lightstone L, Praga M Kidney Int Rep. 2025; 10(2):432-446.

PMID: 39990880 PMC: 11843281. DOI: 10.1016/j.ekir.2024.10.023.


Nearing the Finish Line: Steady Progress in the Development of Complement Inhibitors for Glomerular Disease.

Thurman J Kidney Int Rep. 2025; 10(2):302-305.

PMID: 39990875 PMC: 11843313. DOI: 10.1016/j.ekir.2024.11.1370.


Kidney Transplantation in Children and Adolescents With C3 Glomerulopathy or Immune Complex Membranoproliferative Glomerulonephritis: An International Survey of Current Practice.

Patry C, Webb N, Meier M, Pape L, Fichtner A, Hocker B Pediatr Transplant. 2025; 29(2):e70048.

PMID: 39989336 PMC: 11848702. DOI: 10.1111/petr.70048.


References
1.
Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams C . Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A. 2019; 116(16):7926-7931. PMC: 6475383. DOI: 10.1073/pnas.1820892116. View

2.
Heiderscheit A, Hauer J, Smith R . C3 glomerulopathy: Understanding an ultra-rare complement-mediated renal disease. Am J Med Genet C Semin Med Genet. 2022; 190(3):344-357. PMC: 9613507. DOI: 10.1002/ajmg.c.31986. View

3.
Dixon B, Greenbaum L, Huang L, Rajan S, Ke C, Zhang Y . Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases. Kidney Int Rep. 2023; 8(11):2284-2293. PMC: 10658235. DOI: 10.1016/j.ekir.2023.08.033. View

4.
Medjeral-Thomas N, OShaughnessy M, ORegan J, Traynor C, Flanagan M, Wong L . C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol. 2013; 9(1):46-53. PMC: 3878702. DOI: 10.2215/CJN.04700513. View

5.
Smith R, Alexander J, Barlow P, Botto M, Cassavant T, Cook H . New approaches to the treatment of dense deposit disease. J Am Soc Nephrol. 2007; 18(9):2447-56. PMC: 4853920. DOI: 10.1681/ASN.2007030356. View